The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An <i>In Silico</i> Study.

ABSTRACT: Cancer somatic mutations have been identified as a source of antigens that can be targeted by cancer immunotherapy. In this work, expanding on previous studies, we analyze the HLA-presentation properties of mutations that are known to drive resistance to cancer targeted-therapies. We survey a large dataset of mutations that confer resistance to different drugs and occur in numerous genes and tumor types. We show that a significant number of them are predicted in silico to be potentially immunogenic across a large proportion of the human population. Further, by analyzing a cohort of patients carrying a small subset of these resistance mutations, we provide evidence that what is observed in the general population may be indicative of the mutations' immunogenic potential in resistant p

SUBMITTER: Punta M 

PROVIDER: S-EPMC7578429 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature